Question special

We know this patient population is predisposed to having much more thrombotic events and while in the CASSINI trial, researchers looked for DVT, this was absent in the AVERT trial which will lead to a diagnosis in one group vs under diagnosis in the next. In addition, cancer categories in each group was very different, could this have contributed to the different findings?